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Marine oils gained prominence following the report that Greenland Inuits who consumed a high-fat diet
rich in long-chain n-3 polyunsaturated fatty acids (PUFAs) also had low rates of cardiovascular disease.
Marine n-3 PUFAs have since become a billion dollar industry, which will continue to grow based on
current trends. However, recent systematic reviews question the health beneﬁts of marine oil supple-
ments, particularly in the prevention of cardiovascular disease. Marine oils constitute an extremely
complex dietary intervention for a number of reasons: i) the many chemical compounds they contain; ii)
the many biological processes affected by n-3 PUFAs; iii) their tendency to deteriorate and form
potentially toxic primary and secondary oxidation products; and iv) inaccuracy in the labelling of con-
sumer products. These complexities may confound the clinical literature, limiting the ability to make
substantive conclusions for some key health outcomes. Thus, there is a pressing need for clinical trials
using marine oils whose composition has been independently veriﬁed and demonstrated to be mini-
mally oxidised. Without such data, it is premature to conclude that n-3 PUFA rich supplements are
ineffective.
© 2016 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
In 1971, Bang and Dyerberg reported low rates of cardiovascular
disease in Greenland Inuits who consumed a fatty diet made up
almost exclusively of oily ﬁsh and seal meat, a paradox given the
contemporary understanding of the association between dietary fat
and cardiovascular disease [1]. While this observation has recently
been questioned [2], it sparked considerable scientiﬁc interest.
Since then, a vast scientiﬁc literature has emerged exploring the
health effects of marine oils rich in n-3 polyunsaturated fatty acids
(PUFAs), in particular the long chain eicosapentaenoic acid (EPA)
and docosahexaenoic acid (DHA). Alongside, a billion dollar in-
dustry has arisen [3], marketing ﬁsh oil and other marine oils to
consumers, such that marine oils are now one of the most popular
supplements worldwide [4]. In the USA, they are used by 6.5% of the
population (37% of supplement users) [4] and 8% of college students
[5]. In a study in New Zealand, 15% of women undergoing fertility
treatment were taking marine oil supplements [6].ty of Auckland, Private Bag,
rt).
n open access article under the CCIn many ways, scientists and physicians have approached ma-
rine oils as they would a medication, investigating their health
effects using randomised controlled trials, with controlled doses,
for speciﬁc indications. Marine oils have a long list of apparent
indications, including prevention of cardiovascular disease [7] and
cognitive decline [8], improvement of infant neurodevelopment
[8], and treatment of inﬂammatory diseases such as rheumatoid
arthritis and asthma [9]. Recommended doses differ depending on
indication [9,10], and products are labelled so that consumers can
determine a target dose of n-3 PUFAs.
However, there is increasing evidence to suggest that marine
oils are actually ineffective for secondary prevention of cardiovas-
cular disease, which is their highest proﬁle indication [11,12]. In
reality, marine oil supplements are quite unlike medications in
many respects, including the complexity of their biological effects,
their impurity (containing many chemical compounds), the inac-
curacy of labelled content, their potential to degrade to toxic
compounds, and limited regulation of sales and marketing.
Consideration of the complexity of marine oils and the ways they
differ from typical drugs may help explain why they appear not to
have delivered on the promising tale of the Greenland Inuits.BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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There is a very large range of physiological effects associated
with n-3 PUFAs, which is quite unlike most medications.
2.1. Anti-inﬂammatory
They inhibit inﬂammatory processes at 5 distinct levels:
1) Increasing cell membrane ﬂuidity, which interferes with acti-
vation of immune cells such as T-lymphocytes [13].
2) Activating the transcription factors PPAR-a [14] and PPAR-g [15],
and the transmembrane receptor GPR-120 [16], which inhibit
the proinﬂammatory NF-kB pathway [17e19]. This reduces the
production of inﬂammatory cytokines such as TNF-a and IL-6
and cell adhesion molecules such as ICAM and VCAM [9].
3) Competing with n-6 PUFAs as a substrate for the COX-2 enzyme,
shifting the balance of eicosanoids from the proinﬂammatory n-
6 series to the anti-inﬂammatory or less inﬂammatory n-3 series
[9].
4) Competing with n-6 PUFAs as a substrate for endocannabinoid
synthesis, which leads to the production of anti-inﬂammatory
endocannabinoids [9].
5) Forming protectins and resolvins which have a role in ending
the inﬂammatory response [9].2.2. Lipid metabolism
n-3 PUFAs also have important effects on lipid metabolism
through interaction with key transcription factors. They activate
PPAR-a [14] and inhibit SREB1-c [20] and HNF-4a [21] in the liver.
The combined effect is to increase fatty acid b-oxidation for energy
production and reduce lipid synthesis [20,22], reduce hepatic fat
storage [14,23], and limit the release of triglycerides into the cir-
culation [14,23]. PPAR-g is a key regulator of adipose tissue function
that is also activated by n-3 PUFAs [23]. Activation of PPAR-g in-
creases adipogenesis [24], up regulates enzymatic pathways
involved in uptake and storage of lipid [25] and insulin signalling
[26], inhibits free fatty acid release, and normalises adipokine
production [27]. It is noteworthy that the activation of PPAR-g is the
primary mechanism for the insulin-sensitising effects of thiazoli-
dinediones, which are used in themanagement of diabetes mellitus
[26].
2.3. Redox status
While n-3 PUFAs function as antioxidants [28], their impacts on
biological systems are complex. Their participation in redox re-
actions leads to the production of a lipid peroxide radical, which
itself is highly reactive [29]. In one study, lower doses of n-3 PUFAs
had an antioxidant effect, but higher doses (1600 mg/day) were
associated with increased markers of oxidative damage [30]. Aside
from dose, many other factors are likely to inﬂuence the redox ef-
fect of n-3 PUFAs, including the degree to which the oil was oxi-
dised prior to consumption, the concentration of antioxidants in
the oil, and the endogenous antioxidant status of the consumer.
Further, as obesity, inﬂammation, infection, and hyperglycaemia all
inﬂuence oxidative stress [31,32], many aspects of health may
modulate the redox effects of marine oils.
2.4. Central nervous system
DHA is a major structural component of the central nervous
system and the retina, making up 35% of fatty acids within synapticmembranes [33]. There is rapid uptake of DHA in late gestation [34]
and infancy [35], and deﬁciency is associated with cognitive defects
in animal models [36]. Supplementation with n-3 PUFAs has been
investigated as a treatment for a wide range of neurological and
psychiatric disorders, and they are frequently taken during preg-
nancy or infancy with the aim of improving neurodevelopment
[6,8].
n-3 PUFAs also have anti-arrhythmic properties [37], and like
any fatty acid can be stored in adipose tissue or undergo b-oxida-
tion for energy production.
2.5. Diversity of effects
As outlined above, n-3 PUFAs have a wide diversity of effects
through many different mechanisms. Whilst it could be assumed
that these are synergistic, some of these effects may be conﬂicting.
Ferrannini observed that medications that have a very speciﬁc
action (affecting a single metabolic pathway) are usually preferable,
because unintended/unpredicted adverse effects are less likely [38].
The statins (a class of drugs that reduce synthesis of cholesterol by
inhibiting the enzyme HMGeCoA reductase) are a good example
[38]. In contrast, the thiazolidinediones act through PPAR-g, which
is expressed in many tissues, and has many transcriptionally-
regulating actions [26]. While these drugs do have important in-
sulin sensitising effects, reports have shown an increased risk of
congestive heart failure [39] and fractures [40]. From this
perspective, marine oils, which affect many pathways in addition to
PPAR-g, have greater potential for unpredictable and potentially
adverse effects.
Importantly, the multiple mechanisms by which n-3 PUFAs
modulate inﬂammation andmetabolismmay alsomake it harder to
translate the results of animal studies to humans. To standardise
between species, doses are often considered adjusted for weight or
body surface area [41]. This is reasonable if there is only one
mechanism of action, as if there are differences in the afﬁnity of
enzymes or receptors for a drug or compound of interest, these are
likely to differ by a constant factor, which may simply change the
required dose to achieve a biological effect. However, when there
are multiple distinct biological effects, such as for n-3 PUFAs, it is
possible that the activity through each mechanism could vary by a
different factor. In that case, the overall effect in different species
would be very difﬁcult to predict. Notably, the insulin-sensitising
effects of marine oils have not clearly translated from rodents
[16] to humans [42].
3. Marine oils contain more than n-3 PUFAs
The n-3 PUFAs EPA and DHA are considered to be the active
compounds in marine oils, and the typical labelled content is be-
tween 300 and 600 mg/g of oil. However, marine oils also contain
signiﬁcant quantities of monounsaturated and saturated fatty acids,
as well as small amounts of n-6 PUFAs. Further, in addition to fatty
acids, there are other chemical species, including fat-soluble vita-
mins, carotenoids, phospholipids, cholesterol, and glycerol. In fact,
two recent clinical trials that presented an independently
measured fatty acid proﬁle of the trial oil showed that the fatty acid
content was only 42% of the oil mass in a krill-salmon blended oil
[43] and 75% in a ﬁsh oil [44].
Oils made from krill are becoming an increasingly popular
source of n-3 PUFAs. These oils may contain an evenwider range of
chemical components as the fatty acids are in the form of phos-
pholipids [45,46], which have water-soluble and lipid-soluble
poles. Thus, krill oils may also contain water-soluble molecules. In
a randomised controlled trial of krill-salmon blended oil, supple-
mentation lead to reduced insulin sensitivity, which was unlikely to
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4. Current understanding of the health effects of marine oils
4.1. Early trials
Initial evidence from clinical trials suggested cardiovascular,
anti-inﬂammatory, and cognitive beneﬁts of n-3 PUFA supple-
mentation. It was shown to reduce plasma triglyceride levels [47],
lower blood pressure [48], reduce platelet aggregation [49], and
stabilise atherosclerotic plaque [50]. Together these effects would
be expected to slow atherosclerosis and reduce the tendency of
atherosclerotic plaques to rupture, thrombose, and occlude (i.e. the
processes leading to myocardial infarction). Further, the reported
anti-arrhythmic effects [51] might prevent sudden death after
myocardial infarction. Some trials are consistent with this,
including the open-label GISSI-Prevenzione [52] and JELIS [53]
trials. Similarly, the anti-inﬂammatory effects of n-3 PUFAs would
suggest a useful role in the treatment of inﬂammatory diseases [9],
and beneﬁt has been demonstrated in the treatment of rheumatoid
arthritis [54,55].
4.2. Systematic reviews
With the growing number of trials of n-3 PUFAs, there has been
progression to detailed systematic reviews that have cast doubt on
the beneﬁts suggested by early trials. Recent systematic reviews of
randomized placebo-controlled trials on the use of n-3 PUFAs for
secondary prevention of cardiovascular disease showed no effect
on the risk ofmyocardial infarction or sudden death [11,12]. Further,
there was no overall effect in the treatment of asthma or inﬂam-
matory bowel disease, with individual trials showing conﬂicting
results [56,57]. Recent systematic reviews have also found no
overall effect of n-3 PUFA supplementation on a variety of preg-
nancy outcomes, including gestational diabetes, preterm birth, pre-
eclampsia, intrauterine growth restriction, and measures of infant
neurodevelopment [58e60], but yet again the individual trial data
are mixed [58e60].
4.3. Conﬂicting results
Together, these data suggest that n-3 PUFAs have little overall
effect on cardiovascular risk, pregnancy outcomes, and some in-
ﬂammatory diseases. However, other potential explanations for a
mixed and overall negative literature have been raised. These
include heterogeneity of the study populations and their back-
ground ﬁsh consumption, the trial dose of n-3 PUFAs, the appro-
priateness of the chosen placebos and study outcomes, as well as
concomitant medications [57,61,62]. A possible explanation that
has received little attention [63,64], is that there is substantial
variability in the composition of marine oils sold at retail, which
may often contain potentially toxic oxidation products in excess of
industry standards [65e67], lower than labelled concentrations of
n-3 PUFAs, and variation in the ratio of EPA and DHA [67e70].
5. Oxidation of n-3 PUFAs
n-3 PUFAs are highly prone to oxidative degradation, owing to
their many double bonds that have a low activation energy for free
radical formation [29]. Oxidation is a highly complex process, and
the degree and rate of oxidation of a marine oil is inﬂuenced by
many factors, including the fatty acid composition, antioxidant
content, temperature, exposure to oxygen and light, and the pres-
ence of water and heavy metals [29]. Importantly, added antioxi-
dants reduce, but do not prevent oxidation during storage [71].The initial step of oxidation leads to increased levels of hydro-
peroxides, which decompose into a variety of radicals. These react
with unoxidised PUFAs to form additional hydroperoxides, while
also breaking down to form a wide range of secondary oxidation
products, such as volatile ketones and alcohols that contribute to
the smell of rancid oil [29].
While measurement of speciﬁc chemical species is difﬁcult,
simple industry standard tests provide a proxy measure of oxida-
tive products. The peroxide value (PV) provides a quantitative
measure of hydroperoxide concentration. However, the most
common method to estimate secondary oxidation is the p-anisi-
dine value (AV), which measures aldehydic compounds. Note that
the AV can be increased by some ﬂavourings (such as citrus oils)
[72], but it remains the recommended test for estimating secondary
oxidation [73,74]. By measuring both PV and AV, primary and sec-
ondary oxidation products are characterised, enabling an overall
assessment of the degree of oxidation, which is reﬂected in the
Totox value (2PV þ AV). A number of authorities have published
maximum limits of oxidation in ﬁsh oils, most commonly set as
PV < 5, AV < 20, Totox < 26 [73e75]. Notably, there are insufﬁcient
data to indicate safe levels of oxidation for human consumption,
and these limits based on palatability provide the only available
reference point.
There are now multiple studies from around the world indi-
cating that retail n-3 PUFA supplements are frequently oxidised
above these limits. These include 31% [76] and 50% [66] of products
tested in independent Canadian studies, 44% in Brazil [77], 84% in
South Africa [65], and 92% in New Zealand [67]. Of note, one of the
Canadian studies [66] included plant-based oils, which are less
prone to oxidation and therefore underestimated the problem. In
addition, Labdoor, a for-proﬁt company from the United States that
tests and sells supplements, reported that 28% of products tested
had greater than twice the recommended level of lipid peroxides
[78]. Together this indicates that consumers purchasing marine oil
products are likely to be exposed to excess lipid oxidation products.
Importantly, it appears that there are no reliable indicators that a
consumer could use to select an unoxidised product, since cost, best
before date, and country of manufacture country were not associ-
ated with differences in oxidation levels [67].
6. Safety of oxidised marine oils
The safety of lipid oxidation products present in marine oils is
poorly understood. Studies in a variety of animal models have
shown toxic effects including growth retardation and organ toxicity
[79]. In a rabbit model, supplementation with ﬁsh oil led to a
marked increase of lipid peroxidation products in serum and
accelerated atherosclerosis [80]. A plausible mechanism is through
oxidation of LDL particles, as lipid oxidation products are trans-
ported within LDL particles [81], which must be oxidised before
they can be incorporated into the foam cells of atherosclerotic
plaques [82e84]. Further, lipid oxidation products are mutagenic
[85,86], and could increase the risk of malignancy. However, the
comparatively high doses and unusual methods of administration
used in many animal toxicity models make translation to humans
difﬁcult. In one human study, short-term supplementation with
oxidised ﬁsh oil, did not affect markers of oxidative stress [87], but
long-term effects on organ function, atherosclerotic cardiovascular
disease or the risk of cancer have not been assessed.
It is important to consider that many ﬁsh oil consumers may be
especially vulnerable to toxic effects. For example, marine oils are
used in both primary and secondary prevention of cardiovascular
disease. Many of these consumers are at increased cardiovascular
risk, for example due to obesity, diabetes, increasing age, or a his-
tory of ischaemic heart disease. Thus, if oxidised marine oils
B.B. Albert et al. / Journal of Nutrition & Intermediary Metabolism 5 (2016) 3e106increase the rate of atherosclerosis, they may be of greater harm in
such populations. Pregnant women are another particularly
vulnerable population, who consumemarine oils primarily because
of purported beneﬁts to neurodevelopment of the fetus. Pregnancy
is a time associatedwith reduced endogenous antioxidants, and the
early embryo has very little antioxidant defence. A recent study has
suggested potential adverse effects of ﬁsh oil on neurodevelopment
of the offspring, although the oxidative state of the trial oil was not
reported [88].
Given the high frequency of oxidised supplements on the retail
market, it is likely that in many clinical trials of n-3 PUFAs the oil
has been oxidised. Current evidence is insufﬁcient to determine
whether oxidised supplements have poorer efﬁcacy or have
adverse effects on health. Thus, oxidation remains a potential
explanation for the mixed literature investigating the effects of n-3
PUFA supplementation.
7. Marine oils and labelled n-3 PUFA content
Unlikemedications where consumers and physicians can rely on
accurate and consistent dosing, the accuracy of supplement labels
is often poor. Studies of marine oil products from Africa [65,70],
Australasia [67,89,90], North America [68,69,76], South America
[77] and Europe [68,91] have examined the accuracy of labelled n-3
PUFA content of ﬁsh oils. Opperman et al. arbitrarily but reasonably
deﬁned adequate accuracy as n-3 PUFA content between 90% and
110% of that labelled [70]. Using this threshold, in 6 of the 10 studies
at least 30% of products under-delivered [65,67e70,89], while in 4
studies more than half of the products tested under-delivered
[67e70].
Thus, many products sold at retail have less n-3 PUFA content
than labelled. This is a potential problem both for clinical trial
participants and consumers, as it limits their ability to take a target
dose of n-3 PUFAs. This may also hinder interpretation of the trial
literature, as an independent analysis of trial oils is usually not
reported, so that trials failing to demonstrate effects may have
inadvertently under-dosed participants. As a result, the failure of
marine oil supplements to alter hard cardiovascular outcomes in
the current literature might be explained by excess oxidation
products and inaccurate dosing.
8. Beneﬁts of ﬁsh consumption: beyond n-3 PUFAs
In contrast to the evidence for marine oil supplements, there is
substantial epidemiological evidence that ﬁsh consumption is
associated with reduced cardiovascular [92e96] and cerebrovas-
cular risk [97]. Further, greater circulating n-3 PUFA levels are also
associated with greater insulin sensitivity [98,99] and a reduction
in sudden cardiovascular death [100,101]. However, it is important
to recognise that in cross-sectional and epidemiological studies n-3
PUFA levels are markers of ﬁsh consumption (not ﬁsh oil). Thus, it
may not be the circulating n-3 PUFAs per se that account for the
reduced risk.
Fish consumption differs from supplementation with marine oil
by three major factors. Firstly, eating a meal of ﬁsh displaces other
foods from the diet, such as red meat that is rich in saturated fat.
Secondly, ﬁsh meat has substantial protein content [102]. Con-
sumption of ﬁsh protein has important biological effects in humans,
including antihypertensive [103] and insulin-sensitising effects
[104]. Salmon calcitonin, which inhibits bone resorption in humans
[105], has been detected in plasma after salmon feeding in rats
[106], suggesting it might convey some of the biological effects of
salmon consumption. Interestingly, ﬁsh protein also reduces uri-
nary 8-OH deoxyguanosine [103] (a marker of oxidative DNA
damage), so that when ﬁsh meat is consumed, the proteincomponent might help to counter potential oxidative stress asso-
ciated with the n-3 PUFAs. Thus, some of the beneﬁcial effects of
ﬁsh consumption are likely to be due to its protein content. Lastly,
while consumers of ﬁsh oil are frequently exposed to excess
oxidation products, this is unlikely to occur with ﬁsh consumption,
as rancid ﬁsh is malodourous and unpalatable.
9. Alternative approaches to getting the beneﬁt of n-3 PUFAs
Many problems with the use of marine oils as an intervention
have been discussed, including the complex chemical composition,
many biological effects, presence of oxidation products, and prob-
lems with the accuracy of dosing. In this light, two diametrically
opposite directions should be considered.
Firstly, rather than using ﬁsh oil, oily ﬁsh as awhole foodmay be
a better intervention to improve cardiovascular risk. Current evi-
dence clearly indicates that it is beneﬁcial, which is not true of
marine oils [96]. The Heart Foundation of Australia recommends
that 2e3 servings of ﬁsh are consumed each week [107]. This is
reasonable but may not be achievable at a population level, since
ﬁsh is costly, many people do not like it, and there are concerns
about the sustainability of ﬁsheries. It appears that the greatest
incremental beneﬁt is observed between those who eat ﬁsh very
rarely and those eating ﬁsh once per week [95], suggesting that one
ﬁsh meal per week may be an appropriate minimum intake.
Secondly, a precise pharmacological approach might be more
efﬁcacious than supplementation with marine oils. Many drugs
already modulate the pathways affected by n-3 PUFAs, including
the thiazolidinediones (PPAR-g), ﬁbrates (PPAR-a), and salicylates
(COX-2 and NF-kB). Recent evidence showed that the cell surface
receptor GPR-120 mediates the insulin-sensitising effect of n-3
PUFAs in rodents, through reduced inﬂammation of adipose tissue
[16]. In obesity, adipose tissue inﬂammation leads to abnormal
release of free fatty acids and adipokine production [108], which in
turn lead to insulin resistance [109], the major factor that connects
obesity to hypertension, dyslipidemia, type 2 diabetes, and car-
diovascular disease [110]. Thus, GPR-120 may be an especially
promising target for drug development, which may improve car-
diometabolic risk. Importantly, a synthetic GPR-120 agonist confers
the same insulin-sensitizing effect as n-3 PUFAs in rodents [111].
Further, GPR-120 also has effects on the regulation of appetite [112]
and insulin secretion [113,114]. While there are currently no data on
the effects of a GPR-120 agonist in humans, a report indicating that
patients with GPR-120 mutations develop obesity and insulin
resistance [115] suggests that the effect could translate to humans.
Because of the central importance of insulin sensitivity to car-
diometabolic risk [110], if GPR-120 agonists do improve insulin
sensitivity, they could potentially ameliorate much of the disease
risk associated with obesity. Notably, their action through a single
receptor may increase the likelihood that effects can be successfully
translated from rodent models to humans without unexpected
adverse effects. Lastly, it is likely that a synthetic agonist would be
chemically stable, with reliably reported active ingredient, and
require a smaller mass of medication than the many marine oil
capsules needed to reach a high n-3 PUFA dose.
10. Market success in the face of weakening scientiﬁc
evidence
The great promise for n-3 PUFAs emerging out of the 1970s has
not been conﬁrmed by contemporary trials and systematic reviews.
Yet, while the evidence base has eroded, the market for marine oil
supplements has grown substantially [116], and is expected to
reach US$ 1.7 billion by 2018 [3]. This implies that the marketing is
disconnected from the current scientiﬁc evidence.
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are regulated and marketed in many countries. For example, in the
United States [117], Australia [118], and New Zealand [119], it is not
necessary to prove the efﬁcacy or safety of supplements prior to
marketing, and there is no formal post-marketing safety surveil-
lance to detect potential uncommon adverse events. In these
countries, while speciﬁc claims such as treating or curing a disease
cannot be made without strong supporting evidence, 'structure/
function claims' (i.e. that a supplement can promote, maintain or
enhance health or well-being, or affect the structure or function of
an organ or the body) can be made with minimal support
[117,120e122]. In Europe, the bar is set higher as “general health
claims” for supplements must be submitted to the European Food
Safety Authority for review, who consider the scientiﬁc evidence
and publish lists of allowable and non-allowable claims [123].
Allowable claims for n-3 PUFA rich supplements in Europe include
that they contribute to the normal function of the heart, and to the
maintenance of normal blood pressure and triglycerides [124]. In
contrast, n-3 PUFA rich supplements cannot be claimed to help
maintain normal blood glucose or LDL-cholesterol [124]. This type
of regulation, while more costly, reduces the range of general
claims to those that are probably true to some extent.
Nevertheless, structure/function claims and even the approved
general claims in Europe are likely to confuse many consumers. For
example, across all of the discussed regions, ﬁsh oil products could
not be claimed to “prevent myocardial infarction”, but they could
be claimed to “support cardiovascular health”. These two claims are
technically very different, but it is likely that many (if not most)
consumers would interpret them in the same way. This would
hamper the ability of consumers to make an informed decision
about supplements, and may in part explain the continued success
of marine oils in the face of weakening evidence for beneﬁt
[3,116,125]. Importantly, outside of Europe, because structure/
function claims are vague and not based on scientiﬁc evidence, they
do not need to be changed in light of new evidence to the contrary.
11. Regulation and the unknown risk to consumers of
oxidised marine oils
Weak regulation of health supplements around the world en-
ables them to be sold without ﬁrst determining their safety
[117e119], and this has the potential to allow harmful substances to
be sold as supplements. Marine oils that have become oxidisedmay
be such a product. Reports from around the world including Aus-
tralasia, Africa, North America, and South America have shown a
high frequency of oxidation above recommended limits
[65e67,76e78]. Further, not only have some of these studies
included products imported from other regions [66,67], but most
ﬁsh oils are actually sourced from the West coast of South America,
where they undergo the same initial steps in manufacture [64].
Thus, oxidation of marine oil supplements is likely to be a global
problem, and the risk to consumers remains unknown.
In this light, it is important to consider whether current regu-
lation is sufﬁcient to keep consumers safe. European regulation of
supplements is stronger than in other regions, and the European
Food Safety Authority (EFSA) has given some consideration to the
oxidation of ﬁsh oil supplements [73]. In their report, they indi-
cated that there were insufﬁcient data to set a safe limit of oxida-
tion products, and recommended that the effects of individual
oxidation products on human health be investigated [73]. However,
despite this lack of evidence, as has occurred outside of Europe,
marketing has been allowedwithout any requirement to determine
safety prior to sale or afterwards. As a result, this issue has been
barely investigated and all oxidation limits are arbitrary and based
on palatability, whether published by the EFSA (Europe) [73], Foodand Drug Administration (USA) [126], Therapeutic Goods Admin-
istration (Australia) [127], Health Canada [74], the Codex Ali-
mentarius Commission (draft) representing the World Health
Organisation and Food and Agriculture Organisation of the United
Nations [128], or industry groups such as the Global Organisation
for EPA and DHA [129] or Council for Responsible Nutrition [75].
While the appropriateness of these limits is unknown, they are
frequently exceeded in retail products [65e67,76e78]. This sug-
gests that oxidation of marine supplements is rarely audited,
testing is unreliable, or the oil tested is not representative of that
available for purchase at retail. Nonetheless, despite this fact, we
believe that the most pressing issue in the regulation of marine oil
supplements is not enforcement of oxidation limits, but establish-
ment of what those limits should be. Regulation should have
compelled studies investigating safe limits of oxidation to be per-
formed and funded, but it is clear that this has not been the case. In
the absence of such regulation, this has been left to independent
members of the scientiﬁc community.
12. Conclusions
Supplementation with marine oils constitutes a complex inter-
vention. In addition to having a broad range of chemical com-
pounds, the n-3 PUFAs that are considered to be the active
ingredients affect a wide range of biological processes in many
different tissues. Further, oxidation products may also have
important adverse biological effects. The current scientiﬁc litera-
ture, which has increasingly shown no overall beneﬁt of marine
oils, may have been confounded by other oil components (including
unrecognised oxidation products), as well as inadvertent under-
dosing of participants. Thus, there is a pressing need for trials to
be conducted with supplements where content is independently
veriﬁed and the oxidative state is determined. Until these data
emerge, we cannot be sure that marine oils are as ineffective as
current evidence suggests. It is important that a potentially effec-
tive treatment such as marine oils is not discarded out of hand.
However, there is also a need for studies investigating the potential
toxicity of speciﬁc marine oil oxidation products. In the meantime,
consumption of oily ﬁsh can be recommended to reduce cardio-
vascular risk, and the development of drugs targeting speciﬁc
pathways that are affected by n-3 PUFAs may provide greater
beneﬁt still. Lastly, the poor regulation of supplements and their
label claims serves to confuse consumers, such that the market
success of marine oils far exceeds the scientiﬁc evidence. As it
stands, current evidence suggests that consuming marine oil sup-
plements is not money well spent.
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